The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated
